Today's Rundown J&J allies with BARDA to accelerate coronavirus vaccine program Bayer moves 400 R&D jobs to CRO-run small molecules unit ALX raises $105M for midphase trials of CD47 cancer drug Ligand snags Roche-partnered drug in Icagen buyout Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows Calling vaccine makers: Moderna, NIH need a partner to produce their coronavirus shot New startup uses fine retinal movements as a window into brain health Featured Story | | | Wednesday, February 12, 2020 Johnson & Johnson has teamed up with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine against coronavirus. J&J is pooling money and resources with BARDA in an attempt to accelerate the progress of a vaccine candidate into phase 1 development. |
|
|---|
|
| | QUALITY. SPEED. VALUE.
You Can Have It All. We have successfully delivered therapeutic-quality antibodies to our partners for even the most challenging projects. We deliver lead candidates in a greater number and in a shorter timeline than other CROs that use transgenic animals, in vitro display or humanization. Our expert team of scientists can do the same for your antibody discovery project. Contact us at info@alivamab.com to learn more alivamab.com |
Top Stories Wednesday, February 12, 2020 Back in 2018, Bayer mulled outsourcing R&D as part of a greater restructuring. Now, the company is pulling the trigger on that plan, transferring 400 staffers to a “full-fledged research center” to be set up by Nuvisan, a German CRO, in Berlin. The deal is slated to close by the middle of this year. Wednesday, February 12, 2020 ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Wednesday, February 12, 2020 Ligand Pharmaceuticals has acquired a Roche-partnered program from Icagen. The deal comes a little more than one year after Roche and Icagen entered into a drug discovery pact aimed at neurological disorders. Wednesday, February 12, 2020 Pancreatic cancer remains difficult to treat, with a five-year survival rate of around 10%. While looking for ways to tackle the deadly tumor, scientists at Queen Mary University of London, AstraZeneca and ADC Therapeutics identified an unexpected ally: the virus that causes foot-and-mouth disease in cows. Wednesday, February 12, 2020 Moderna and the NIH put their coronavirus vaccine R&D into high gear. But the partners need a manufacturer, and no major pharma has stepped up. Why? Companies might not want to sacrifice capacity for their own profit-making vaccine prospects. Wednesday, February 12, 2020 By measuring the minuscule motions of the human eye—and tracking the movements of the retina on a cellular level—a startup hopes to open new windows into a person’s neurological health. | | [Survey] Bioavailability Toolkit Share insight on the drug developer’s perspective on bioavailability enhancement technologies and the reasoning behind the use of certain technologies in preclinical and early-stage clinical development. Take survey. |
Resources Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: USDM Life Sciences Details on the FDA’s upcoming Computer System Validation guidance Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. 11th Annual SCOPE Summit: Summit for Clinical Ops Executives February 18-21, 2020 | Orlando, FL BioBasics 101: The Biology of Biotech March 26-27, 2020 | Boston, MA BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA BIO International Convention June 8-11, 2020 | San Diego, CA Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 